Evacetrapib是一种有效且选择性的CETP抑制剂，其对重组人CETP蛋白的IC50为5.5 nM，在人血浆中抑制CETP活性的IC50为36 nM。
|
英文别名 (English Synonym) |
Evacetrapib (LY2484595) |
|
中文名称 (Chinese Name) |
|
|
靶点 (Target) |
CETP |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
1186486-62-3 |
|
分子式 (Formula) |
C31H36F6N6O2 |
|
分子量 (Molecular Weight) |
638.65 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-2176. doi: 10.1194/jlr.M018069. Epub 2011 Sep 25. PMID: 21957197; PMCID: PMC3220285.
